Synexus exceeds expectations in clinical trial recruitment

Tuesday, October 25, 2011 01:53 PM

Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

Janssen, a pharmaceutical company of Johnson & Johnson, established more than 99 sites across the globe to enroll the more than 716 patients needed for the study. Synexus, which is the largest multi-national company entirely focused on the recruitment and running of clinical trials at its own dedicated research centers, exceeded its recruitment target by more than 50% at its Watermeyer site in Pretoria.

Synexus country manager Dr. Sanet Aspinall commented, “We are often able to exceed our pharma and CRO client’s expectations as we have a very effective enrollment team to recruit patients from the large pool of people surrounding our research centers. This team has developed a sophisticated outreach program which works closely with GPs, primary care clinics and public hospitals in order to find the right patients quickly.”

Linda Roach, the GCO country manager of Janssen Pharmaceuticals in South Africa said, “Within our regulatory environment here in South Africa, we need to partner with sites that can enroll quickly with quality data and can support our efforts to achieve our recruitment targets. Synexus Watermeyer site in Pretoria is one such site."

"This is of particularly importance in South Africa as regulatory timelines can be slow leaving a shorter time frame in which to find these patients. Selection of the right site and infrastructure for this study has proven that, the country can not only deliver but exceed the target number of patients,” Roach continued.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs